サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1562380

アジア太平洋地域のサルコペニア治療：2030年市場予測- 地域別分析- 治療タイプ別、流通チャネル別

Asia Pacific Sarcopenia Treatment Market Forecast to 2030 - Regional Analysis - by Treatment Type and Distribution Channel

出版日
ページ情報
英文 78 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
アジア太平洋地域のサルコペニア治療：2030年市場予測- 地域別分析- 治療タイプ別、流通チャネル別
出版日: 2024年07月04日
発行: The Insight Partners
ページ情報: 英文 78 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

アジア太平洋のサルコペニア治療市場は、2022年には6億9,685万米ドルと評価され、2030年には11億6,404万米ドルに達すると予測され、2022～2030年のCAGRは6.6%と推定されます。

臨床試験段階の製品がアジア太平洋のサルコペニア治療市場を牽引

サルコペニア治療市場に参入する大手企業数社は、サルコペニア治療の開発にますます注力しています。現在、新規のサルコペニア治療が開発され、臨床試験が行われています。

そのため、臨床開発の異なる段階にある薬剤のパイプラインの新興は、サルコペニア治療市場の成長にとって大きな機会となります。

アジア太平洋のサルコペニア治療市場概要

アジア太平洋のサルコペニア治療市場は、中国、インド、日本、韓国、オーストラリア、その他のアジア太平洋に区分されます。アジア太平洋は予測期間中、世界市場で最も速いCAGRを記録すると予測されます。アジアは世界で最も人口が多く、急速に高齢化が進んでいる大陸であり、サルコペニアに関連する問題はアジアのいくつかの国々で蔓延しつつあります。アジア人のライフスタイルは欧米人とは大きく異なり、食習慣も異なります。アジアでは、高齢者のサルコペニアは女性（有病率7.7～21.8％）よりも男性（有病率9.6～22.1％）に多くみられます。Asian Working Group for Sarcopenia（AWGS）は、アジアにおけるサルコペニア研究の促進を目指しています。

アジア太平洋のサルコペニア治療市場の収益と2030年までの予測（金額）

アジア太平洋のサルコペニア治療市場のセグメンテーション

アジア太平洋のサルコペニア治療市場は、治療タイプ、流通チャンネル、国に分類されます。

治療タイプ別に見ると、アジア太平洋のサルコペニア治療市場は、ビタミンD・カルシウムサプリメント、タンパク質サプリメント、ビタミンB12サプリメント、その他に区分されます。2022年のアジア太平洋のサルコペニア治療市場シェアは、ビタミンD・カルシウムサプリメントセグメントが最大でした。

流通チャンネルでは、アジア太平洋のサルコペニア治療市場は薬局、小売チャンネル、オンラインチャンネル、その他に区分されます。2022年のアジア太平洋のサルコペニア治療市場シェアは薬局セグメントが最大でした。

国別では、アジア太平洋のサルコペニア治療市場は中国、インド、日本、オーストラリア、韓国、その他のアジア太平洋に区分されます。2022年のアジア太平洋のサルコペニア治療市場シェアは中国が独占しています。

Abbott Laboratories、Bayer AG、Metagenics LLC、Nestle Health Science SA、Novartis AG、Pfizer Inc、Sanofi SA、Amway Corp、GSK Plcは、アジア太平洋のサルコペニア治療市場で事業を展開している主要企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 アジア太平洋のサルコペニア治療市場-主要産業力学

  • アジア太平洋のサルコペニア治療市場：主要産業力学
  • 市場促進要因
    • 高齢者人口の増加
    • 成人における栄養不良とビタミン欠乏症の増加
  • 主要市場抑制要因
    • 直接的な治療法の入手不可能性
  • 主要市場機会
    • 臨床試験段階の製品
  • 今後の動向
    • サルコペニアに対する意識の高まり
  • 促進要因と抑制要因の影響

第5章 サルコペニア治療市場：アジア太平洋市場分析

  • アジア太平洋のサルコペニア治療市場収益（2020～2030年）
  • アジア太平洋のサルコペニア治療市場の予測と分析

第6章 アジア太平洋のサルコペニア治療市場分析-治療タイプ別

  • ビタミンDとカルシウムサプリメント
  • タンパク質サプリメント
  • ビタミンB12サプリメント
  • その他

第7章 アジア太平洋のサルコペニア治療市場分析-流通チャンネル別

  • 薬局
  • 小売チャンネル
  • オンラインチャンネル
  • その他

第8章 アジア太平洋のサルコペニア治療市場：国別分析

  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • その他のアジア太平洋

第9章 サルコペニア治療市場-業界情勢

  • イントロダクション
  • サルコペニア治療市場における成長戦略
  • 無機的成長戦略
  • 有機的成長戦略

第10章 企業プロファイル

  • Abbott Laboratories
  • Bayer AG
  • Metagenics LLC
  • Nestle Health Science SA
  • Novartis AG
  • Pfizer Inc
  • Sanofi SA
  • Amway Corp
  • GSK Plc

第11章 付録

図表

List Of Tables

  • Table 1. Asia Pacific Sarcopenia Treatment Market Segmentation
  • Table 2. Sarcopenia Drug Under Clinical Development
  • Table 3. Asia Pacific Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Million)
  • Table 4. Asia Pacific Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Million) - By Treatment Type
  • Table 5. Asia Pacific Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Million) - By Distribution Channel
  • Table 6. Asia Pacific Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Country
  • Table 7. China Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 8. China Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 9. India Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 10. India Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 11. Japan Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 12. Japan Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 13. South Korea Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 14. South Korea Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 15. Australia Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 16. Australia Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 17. Rest of Asia Pacific Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Treatment Type
  • Table 18. Rest of Asia Pacific Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn) - By Distribution Channel
  • Table 19. Recent Inorganic Growth Strategies in the Sarcopenia Treatment Market
  • Table 20. Recent Organic Growth Strategies in the Sarcopenia Treatment Market
  • Table 21. Glossary of Terms, Sarcopenia Treatment Market

List Of Figures

  • Figure 1. Asia Pacific Sarcopenia Treatment Market Segmentation, By Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Asia Pacific Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
  • Figure 4. Asia Pacific Sarcopenia Treatment Market Share (%) - By Treatment Type, 2022 and 2030
  • Figure 5. Vitamin D and Calcium Supplement: Asia Pacific Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 6. Protein Supplement : Asia Pacific Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 7. Vitamin B12 Supplement: Asia Pacific Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 8. Others : Asia Pacific Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 9. Asia Pacific Sarcopenia Treatment Market Share (%) - By Distribution Channel, 2022 and 2030
  • Figure 10. Pharmacies : Asia Pacific Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 11. Retail Channels : Asia Pacific Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 12. Online Channels : Asia Pacific Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 13. Others : Asia Pacific Sarcopenia Treatment Market Revenue and Forecasts to 2030 (US$ Million)
  • Figure 14. Asia Pacific Sarcopenia Treatment Market Revenue, by Key Countries, (2022) (US$ Mn)
  • Figure 15. Asia Pacific Sarcopenia Treatment Market Breakdown by Key Countries, 2022 and 2030 (%)
  • Figure 16. China Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 17. India Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 18. Japan Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 19. South Korea Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 20. Australia Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 21. Rest of Asia Pacific Sarcopenia Treatment Market - Revenue and Forecast to 2030(US$ Mn)
  • Figure 22. Growth Strategies in the Sarcopenia Treatment Market
目次
Product Code: BMIRE00030384

The Asia Pacific sarcopenia treatment market was valued at US$ 696.85 million in 2022 and is expected to reach US$ 1,164.04 million by 2030; it is estimated to register a CAGR of 6.6% from 2022 to 2030.

Products in Clinical Trial Phases Drive Asia Pacific Sarcopenia Treatment Market

A few major players operating in the sarcopenia treatment market are increasingly focusing on drug development to treat sarcopenia. Novel sarcopenia treatments are currently being developed and tested in clinical trials. A few of these products are mentioned below:

  • Table 1. Sarcopenia Drug Under Clinical Development

Company Name Interventions Conditions Clinical Trial Stage

Abbott Nutrition Medical Food with AN777

Oral Nutritional Formula Malnutrition

Sarcopenia PHASE3

Nutricia Research Dietary Supplement: Bolus ONS A

Dietary Supplement: Bolus ONS B

Dietary Supplement: Bolus ONS C

Dietary Supplement: Bolus ONS D Sarcopenia PHASE1

Novartis Pharmaceuticals Drug: Bimagrumab Sarcopenia PHASE2

McMaster University Behavioural: Step Reduction Sarcopenia PHASE1

Metabolic Technologies Inc. Dietary Supplement: Placebo

Drug: HMB Plus Vitamin D

Behavioural: Non-Exercise

Behavioural: Exercise Sarcopenia PHASE1

Merck Sharp & Dohme LLC Drug: Comparator MK-077

Drug: Comparator Placebo Sarcopenia PHASE2

Immunotec Inc. Dietary Supplement: Immunocal

Dietary Supplement: Casein Aging and Sarcopenia PHASE2

Lijun Yang Combination Product: 3-Month Intensive Intervention Sarcopenia PHASE4

Regeneron Pharmaceuticals Drug: REGN1033 (SAR391786)

Drug: Placebo Sarcopenia PHASE2

Source: Company Websites and The Insight Partners Analysis

Therefore, the extending pipeline of drugs that are in different stages of clinical development presents significant opportunities for the sarcopenia treatment market growth.

Asia Pacific Sarcopenia Treatment Market Overview

The Asia Pacific sarcopenia treatment market is segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia Pacific. Asia Pacific is expected to register the fastest CAGR in the global market during the forecast period. Asia is the world's most populated continent with a rapidly aging population, and sarcopenia-related issues are becoming more prevalent in several Asian countries. Asians led extremely different lifestyles and follow different dietary habits than people from the Western world. In Asia, sarcopenia in older individuals is more common in males (prevalence 9.6-22.1%) than females (prevalence 7.7-21.8%). Asian Working Group for Sarcopenia (AWGS) aims to promote sarcopenia research in Asia.

Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Sarcopenia Treatment Market Segmentation

The Asia Pacific sarcopenia treatment market is categorized into treatment type, distribution channel, and country.

Based on treatment type, the Asia Pacific sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held the largest Asia Pacific sarcopenia treatment market share in 2022.

In terms of distribution channel, the Asia Pacific sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held the largest Asia Pacific sarcopenia treatment market share in 2022.

By country, the Asia Pacific sarcopenia treatment market is segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific sarcopenia treatment market share in 2022.

Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc are some of the leading companies operating in the Asia Pacific sarcopenia treatment market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Sarcopenia Treatment Market - Key Industry Dynamics

  • 4.1 Asia Pacific Sarcopenia Treatment Market - Key Industry Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Upsurge in Geriatric Population
    • 4.2.2 Rise in Malnutrition and Vitamin Deficiency Among Adults
  • 4.3 Key Market Restraints:
    • 4.3.1 Unavailability of Direct Interventions
  • 4.4 Key Market Opportunities:
    • 4.4.1 Products in Clinical Trial Phases
  • 4.5 Future Trends:
    • 4.5.1 Rising Awareness About Sarcopenia
  • 4.6 Impact of Drivers and Restraints:

5. Sarcopenia Treatment Market - Asia Pacific Market Analysis

  • 5.1 Asia Pacific Sarcopenia Treatment Market Revenue (US$ Million), 2020 - 2030
  • 5.2 Asia Pacific Sarcopenia Treatment Market Forecast and Analysis

6. Asia Pacific Sarcopenia Treatment Market Analysis - By Treatment Type

  • 6.1 Vitamin D and Calcium Supplement
    • 6.1.1 Overview
    • 6.1.2 Vitamin D and Calcium Supplement: Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.2 Protein Supplement
    • 6.2.1 Overview
    • 6.2.2 Protein Supplement : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.3 Vitamin B12 Supplement
    • 6.3.1 Overview
    • 6.3.2 Vitamin B12 Supplement: Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Others
    • 6.4.1 Overview
    • 6.4.2 Others : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Sarcopenia Treatment Market Analysis - By Distribution Channel

  • 7.1 Pharmacies
    • 7.1.1 Overview
    • 7.1.2 Pharmacies : Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)
  • 7.2 Retail Channels
    • 7.2.1 Overview
    • 7.2.2 Retail Channels : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Online Channels
    • 7.3.1 Overview
    • 7.3.2 Online Channels : Asia Pacific Sarcopenia Treatment Market, Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Others
    • 7.4.1 Overview
    • 7.4.2 Others : Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Sarcopenia Treatment Market - Country Analysis

  • 8.1 Asia Pacific
    • 8.1.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
      • 8.1.1.1 Asia Pacific Sarcopenia Treatment Market Revenue and Forecast and Analysis - By Country
      • 8.1.1.2 China Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.2.1 China Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.2.2 China Sarcopenia Treatment Market Breakdown by Distribution Channel
      • 8.1.1.3 India Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.3.1 India Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.3.2 India Sarcopenia Treatment Market Breakdown by Distribution Channel
      • 8.1.1.4 Japan Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.4.1 Japan Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.4.2 Japan Sarcopenia Treatment Market Breakdown by Distribution Channel
      • 8.1.1.5 South Korea Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.5.1 South Korea Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.5.2 South Korea Sarcopenia Treatment Market Breakdown by Distribution Channel
      • 8.1.1.6 Australia Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.6.1 Australia Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.6.2 Australia Sarcopenia Treatment Market Breakdown by Distribution Channel
      • 8.1.1.7 Rest of Asia Pacific Sarcopenia Treatment Market Revenue and Forecast to 2030 (US$ Mn)
        • 8.1.1.7.1 Rest of Asia Pacific Sarcopenia Treatment Market Breakdown by Treatment Type
        • 8.1.1.7.2 Rest of Asia Pacific Sarcopenia Treatment Market Breakdown by Distribution Channel

9. Sarcopenia Treatment Market-Industry Landscape

  • 9.1 Overview
  • 9.2 Growth Strategies in the Sarcopenia Treatment Market
  • 9.3 Inorganic Growth Strategies
    • 9.3.1 Overview
  • 9.4 Organic Growth Strategies
    • 9.4.1 Overview

10. Company Profiles

  • 10.1 Abbott Laboratories
    • 10.1.1 Key Facts
    • 10.1.2 Business Description
    • 10.1.3 Products and Services
    • 10.1.4 Financial Overview
    • 10.1.5 SWOT Analysis
    • 10.1.6 Key Developments
  • 10.2 Bayer AG
    • 10.2.1 Key Facts
    • 10.2.2 Business Description
    • 10.2.3 Products and Services
    • 10.2.4 Financial Overview
    • 10.2.5 SWOT Analysis
    • 10.2.6 Key Developments
  • 10.3 Metagenics LLC
    • 10.3.1 Key Facts
    • 10.3.2 Business Description
    • 10.3.3 Products and Services
    • 10.3.4 Financial Overview
    • 10.3.5 SWOT Analysis
    • 10.3.6 Key Developments
  • 10.4 Nestle Health Science SA
    • 10.4.1 Key Facts
    • 10.4.2 Business Description
    • 10.4.3 Products and Services
    • 10.4.4 Financial Overview
    • 10.4.5 SWOT Analysis
    • 10.4.6 Key Developments
  • 10.5 Novartis AG
    • 10.5.1 Key Facts
    • 10.5.2 Business Description
    • 10.5.3 Products and Services
    • 10.5.4 Financial Overview
    • 10.5.5 SWOT Analysis
    • 10.5.6 Key Developments
  • 10.6 Pfizer Inc
    • 10.6.1 Key Facts
    • 10.6.2 Business Description
    • 10.6.3 Products and Services
    • 10.6.4 Financial Overview
    • 10.6.5 SWOT Analysis
    • 10.6.6 Key Developments
  • 10.7 Sanofi SA
    • 10.7.1 Key Facts
    • 10.7.2 Business Description
    • 10.7.3 Products and Services
    • 10.7.4 Financial Overview
    • 10.7.5 SWOT Analysis
    • 10.7.6 Key Developments
  • 10.8 Amway Corp
    • 10.8.1 Key Facts
    • 10.8.2 Business Description
    • 10.8.3 Products and Services
    • 10.8.4 Financial Overview
    • 10.8.5 SWOT Analysis
    • 10.8.6 Key Developments
  • 10.9 GSK Plc
    • 10.9.1 Key Facts
    • 10.9.2 Business Description
    • 10.9.3 Products and Services
    • 10.9.4 Financial Overview
    • 10.9.5 SWOT Analysis
    • 10.9.6 Key Developments

11. Appendix

  • 11.1 About The Insight Partners
  • 11.2 Glossary of Terms